IE
JBIO

Israel Englander’s Jade Biosciences JBIO Stock Holding History

Israel Englander’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-857
Closed -$49.8K – 6086
2024
Q2 		$49.8K Buy
+857
New +$568K ﹤0.01% 5418

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Israel Englander's JBIO Position: Q2 2026 in Review

Israel Englander increased its Jade Biosciences (JBIO) stake by 97% in Q2 2026, buying an estimated $3.22M and bringing the position to 314,548 shares worth $6.99M. The position accounts for ﹤0.01% of the portfolio, ranked #2673.

Israel Englander first reported a position in JBIO in Q2 2021 and has held it in 16 quarters since. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Israel Englander held 314,548 shares of Jade Biosciences worth $6.99M as of Q2 2026.
  • Israel Englander bought 154,497 Jade Biosciences shares in Q2 2026, an estimated $3.22M.
  • Jade Biosciences made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2673 holding.
  • Israel Englander first reported a position in Jade Biosciences in Q2 2021 and has held it in 16 quarters since.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.